Literature DB >> 32163012

Stool Short-Chain Fatty Acids in Critically Ill Patients with Sepsis.

Beatriz E Valdés-Duque1, Nubia A Giraldo-Giraldo2, Ana M Jaillier-Ramírez3, Adriana Giraldo-Villa4, Irene Acevedo-Castaño5, Mónica A Yepes-Molina6, Janeth Barbosa-Barbosa7, Carlos J Barrera-Causil8, Gloria M Agudelo-Ochoa2.   

Abstract

Objective: To determine the concentration of stool short-chain fatty acids (SCFAs) in critically ill patients with sepsis and to compare the results between the critically ill patient and the control group.
Methods: This descriptive, multicenter, observational study was conducted in five health institutions. Over a 6-month study period, critically ill patients with sepsis who were admitted to the intensive care unit (ICU) and met the inclusion criteria were enrolled, and a control, paired by age and sex, was recruited for each patient. A spontaneous stool sample was collected from each participant and a gas chromatograph coupled to a mass spectrometer (Agilent 7890/MSD 5975 C) was used to measure the concentrations SCFAs.
Results: The final sample included 44 patients and 45 controls. There were no differences in the age and sex distributions between the groups (p > 0.05). According to body mass index (BMI), undernutrition was more prevalent among critically ill patients, and BMI in control subjects was most frequently classified as overweight (p = 0.024). Propionic acid, acetic acid, butyric acid, and isobutyric acid concentrations were significantly lower in the critically ill patient group than in the control group (p = 0.000). No association with outcome variables (complications, ICU stay, and discharge condition) was found in the patients, and patients diagnosed with infection on ICU admission showed significant decreases in butyric and isobutyric acid concentrations with respect to other diagnostic criteria (p < 0.05).Conclusions: The results confirm significantly lower concentrations of stool SCFAs in critically ill patients with sepsis than in control subjects. Due to its role in intestinal integrity, barrier function, and anti-inflammatory effect, maintaining the concentration of SCFAs may be important in the ICU care protocols of the critical patient.

Entities:  

Keywords:  Short-chain fatty acids; acetic; butyric; critically ill patient; intensive care unit; propionic; sepsis

Year:  2020        PMID: 32163012     DOI: 10.1080/07315724.2020.1727379

Source DB:  PubMed          Journal:  J Am Coll Nutr        ISSN: 0731-5724            Impact factor:   3.169


  6 in total

Review 1.  Long-distance relationships - regulation of systemic host defense against infections by the gut microbiota.

Authors:  Jared Schlechte; Isla Skalosky; Markus B Geuking; Braedon McDonald
Journal:  Mucosal Immunol       Date:  2022-06-22       Impact factor: 8.701

2.  Dynamic change of fecal microbiota and metabolomics in a polymicrobial murine sepsis model.

Authors:  Arisa Muratsu; Mitsunori Ikeda; Kentaro Shimizu; Shoichiro Kameoka; Daisuke Motooka; Shota Nakamura; Hisatake Matsumoto; Hiroshi Ogura; Takeshi Shimazu
Journal:  Acute Med Surg       Date:  2022-06-28

Review 3.  Bacteria and Sepsis: Microbiome to the Rescue?

Authors:  Hansol Kang; Ryan M Thomas
Journal:  J Clin Med       Date:  2021-08-14       Impact factor: 4.241

Review 4.  Gut-Lung Crosstalk in Sepsis-Induced Acute Lung Injury.

Authors:  Xin Zhou; Youxia Liao
Journal:  Front Microbiol       Date:  2021-12-23       Impact factor: 5.640

5.  Gut Microbiota Mediates the Susceptibility of Mice to Sepsis-Associated Encephalopathy by Butyric Acid.

Authors:  Huidan Zhang; Jing Xu; Qingrui Wu; Heng Fang; Xin Shao; Xin Ouyang; Zhimei He; Yiyu Deng; Chunbo Chen
Journal:  J Inflamm Res       Date:  2022-03-30

Review 6.  The central and biodynamic role of gut microbiota in critically ill patients.

Authors:  Hannah Wozniak; Tal Sarah Beckmann; Lorin Fröhlich; Tania Soccorsi; Christophe Le Terrier; Aude de Watteville; Jacques Schrenzel; Claudia-Paula Heidegger
Journal:  Crit Care       Date:  2022-08-18       Impact factor: 19.334

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.